Who
In numbers
- Trades disclosed
- 54
- Buys
- 9
- Sells
- 2
- Bought
- $534K
- Sold
- $5.0M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 30 Sep 2019
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,100 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,100 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $7,65015,000 at $0.51 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $52K112,205 at $0.46 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $95K66,929 at $1.42 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —112,205 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,929 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —112,205 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,929 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $7,65015,000 at $0.51 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $52K112,205 at $0.46 | filing |
| 1 Apr 2026filed 2 Apr 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $95K66,929 at $1.42 | filing |
| 5 Jun 2025filed 9 Jun 2025 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —151,316 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,929 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | OCGN OcugenBiotechnology | SEC FORM 4 Bought | $100K200,278 at $0.50 | filing |
| 9 Jun 2023filed 9 Jun 2023 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,205 at $0.00 | filing |
| 7 Jun 2022filed 8 Jun 2022 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,091 at $0.00 | filing |
| 3 Mar 2022filed 4 Mar 2022 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,000 at $0.00 | filing |
News
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaOCGN · manilatimes.net · 14 Oct 2026Ocugen (NASDAQ:OCGN) Stock: Insider Shankar Musunuri Sells 468,727 SharesOCGN · tickerreport.com · 14 Oct 2026Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?OCGN · prnewswire.com · 8 Oct 2026
0 headlines in the last 90 days name Junge Zhang; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.